ArticleCNS neuroscience & therapeutics2026
Inhibition of ASIC1a Attenuates Neuronal Pyroptosis and Neuroinflammation Following Traumatic Brain Injury.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) is a neurological disorder that severely affects health and function. Acid-sensing ion channels 1a (ASIC1a), a proton-gated cation channel permeable to Na
methodsAdult male C57BL/6 mice were subjected to controlled cortical impact (CCI) modeling using weight-drop models. Expression of ASIC1a was evaluated by Western blot and immunofluorescence. Brain water content and neurobehavioral function were tested to assess brain edema and neurological performance. qRT-PCR and Western blot were performed to evaluate the expression of pyroptosis and NF-κB/NLRP3 pathway related markers. ELISA kits were used to measure the levels of IL-1β and IL-18.
resultsOur results demonstrated that ASIC1a expression was upregulated following TBI and localized primarily in neurons. Furthermore, pharmacological inhibition of ASIC1a with PcTx1 significantly attenuated brain edema and improved neurological outcomes in TBI mice. Notably, inhibition of ASIC1a decreased the levels of the pyroptosis-related protein GSDMD-N, as well as the inflammatory cytokines IL-1β and IL-18. Importantly, ASIC1a blockade was associated with the downregulation of the NF-κB/NLRP3 signaling pathway, suggesting that ASIC1a inhibition alleviates neuroinflammatory injury potentially through the modulation of this axis both in vivo and in vitro.
conclusionOur findings implicate ASIC1a as an important modulator of neuroinflammatory progression following TBI. Furthermore, pharmacological inhibition of ASIC1a mitigates neuronal pyroptosis, an effect that is closely associated with the downregulation of the NF-κB/NLRP3 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.